TY PHAR.(SZ:002728)2026-03-25 13:11Group 1: Sales Performance and Projections - In 2025, the core product "Te Yi Brand" cough tablets achieved sales of 636 million pieces, recovering to 63.10% of the same period in 2023, with overall sales better than initial expectations [5] - The company aims to reach an annual sales target of 100 million boxes for cough tablets within approximately five years, increasing pharmacy channel coverage to around 40% [5] - The fourth quarter of 2025 saw sales of 223 million pieces, accounting for 35% of the annual sales, with a significant increase in demand due to the flu season [9] Group 2: Product Development and Market Strategy - The cough tablets have a production capacity of 1.8 billion pieces, which can be increased to 2.4 billion pieces based on market needs [7] - The company plans to enhance the market performance of the skin disease blood toxin pill, which had sales of 15.88 million yuan in 2025, through systematic channel expansion and professional promotion [11] - The company will continue to implement a "1+N" product strategy, focusing on core products while nurturing secondary products like skin disease blood toxin pills and others [12] Group 3: Marketing and Brand Building - In 2025, the company invested 260 million yuan in brand building, transitioning from large-scale investment to refined operations in 2026 [14] - The marketing strategy includes enhancing consumer awareness through content marketing and targeted advertising, optimizing resource allocation between online and offline channels [15] - The company has established a regular inventory monitoring mechanism to maintain healthy inventory turnover, with distributor channel inventory turnover time kept within 30 days [8]